Skip to main content

Table 1 Patient characteristics

From: Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer

Case Age range (y) Weight (kg) Dosage (MBq) Dosage/Weight (MBq/kg) Tumor location Pathologya TNM classification Stage
1 80–89 43.3 142 3.3 L S3 Ade pT1aN0M0 IA
2 70–79 56.5 166 2.9 R S6 SCC cT3N2M0 IIIA
3 80–89 50.0 239 4.8 L S1 + 2 Ade cT2aN0M0 IB
4 60–69 46.3 162 3.5 L S8 SCC pT2aN0M0 IB
5 80–89 52.6 283 5.4 R S7 Ade pT2aN2M0 IB
6 60–69 63.0 164 2.6 R S6 SCC pT1aN0M0 IA
7 70–79 48.6 146 3.0 R S3 Ade pT1bN0M0 IA
8 70–79 46.5 144 3.1 R S2 Ade pT2aN1M0 IIA
9 70–79 72.4 292 4.0 R S5 SCC pT1aN0M0 IA
10 70–79 47.4 242 5.1 R S1 Ade cT4N2M0 IIIB
11 30–39 40.7 147 3.6 R S8 MEDC pT1bN0M0 IA
12 70–79 45.9 294 6.4 L S9 Ade pT1bN0M0 IA
13 50–59 50.0 239 4.8 R S1 Ade pT1aN0M0 IA
14 60–69 65.7 276 4.2 L S1 + 2 SCC cT4N3M1b IV
15 50–59 60.7 294 4.8 L S5 Ade pT2aN1M1b IV
16 60–69 52.1 243 4.7 R S2 SCC cT4N3M0 IIIB
17 80–89 56.2 236 4.2 R S2 Ade pT1aN0M0 IA
18 70–79 57.4 145 2.5 R S7 LCNEC pT2aN2M0 IB
19 70–79 78.4 242 3.1 L S1 + 2 SCC pT1bN0M0 IA
20 50–59 60.6 242 4.0 R S1 Ade pT1bN2M0 IIIA
21 60–69 67.2 243 3.6 L S3 Ade pT3N1M0 IIIA
22 80–89 48.5 240 5.0 R S10 Ade pT2bN0M0 IIA
23 60–69 64.7 243 3.8 L S10 SCC pT3N0M0 IIB
24 70–79 51.4 242 4.7 L S9 Ade pT2bN0M0 IIA
25 60–69 54.8 292 5.3 R S3 Ade pT2aN0M0 IIA
26 60–69 45.9 224 4.9 L S1 + 2 Ade pT4N0M0 IIIA
27 80–89 62.7 242 3.9 L S1 + 2 SCC cT3N0M0 IIB
28 70–79 55.4 146 2.6 R S4 Ade cT2bN1M1b IV
29 60–69 59.4 239 4.0 R S2 Ade pT2bN0M0 IIA
30 70–79 53.0 145 2.7 L S10 PC pT2aN1M0 IIB
31 70–79 55.3 237 4.3 R S1 PC pT1aN0M0 IA
32 70–79 50.7 146 2.9 L S4 Ade pT1aN3M0 IIIB
33 60–69 68.8 274 4.0 R S5 Ade cT2aN2M1 IV
34 60–69 57.2 245 4.3 R S1 SCC cT3N2M0 IIIA
35 70–79 45.6 242 5.3 R S1 Ade pT1aN0M0 IA
36 80–89 54.6 274 5.0 L S1 + 2 Ade pT3N1M0 IIIA
37 70–79 46.6 146 3.1 R S3 Ade pT1aN2M0 IIIA
38 80–89 51.4 292 5.7 R S10 LCNEC pT2aN0M0 IIA
39 80–89 74.8 273 3.6 R S4 Ade pT2aN0M0 IIA
40 60–69 51.9 166 3.2 R S3 Ade cT2aN0M1b IV
41 70–79 40.8 164 4.0 R S3 Ade pT2aN0M0 IB
42 50–59 45.2 166 3.7 L S3 SCC cT4N2M0 IIIB
43 50–59 61.4 266 4.3 R S7 PC pT2aN2M1 IV
44 50–59 72.2 290 4.0 L S10 SCC cT2bN3M0 IIIB
45 60–69 62.4 166 2.7 R S1 LCNEC pT2aN0M0 IIA
46 60–69 54.3 274 5.1 R S8 Ade pT1aN0M0 IA
47 70–79 59.4 164 2.8 R S3 SCC pT2aN0M0 IB
48 60–69 65.6 239 3.6 L S3 Ade pT2aN1M0 IIA
49 70–79 61.9 292 4.7 R S3 SCC pT1bN2M0 IIIA
50 60–69 60.9 290 4.8 R S6 ASCC pT1aN1M0 IIA
  1. aAde adenocarcinoma, SCC squamous cell carcinoma, ASCC adenosquamous carcinoma, PC pleomorphic carcinoma, MEDC mucoepidemoid carcinoma, LCNEC large cell neuroendocrine carcinoma